SCHEMBL25754773

SCHEMBL25754773

CNC(=O)CCCCOCCCn1ccnn1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
HDAC1 Q13547 3/20 0.35
GAA P10253 1/20 0.34
FAAH O00519 1/20 0.34
HTR4 Q13639 2/20 0.33
HPGDS O60760 2/20 0.32
ATP4A P20648 1/20 0.31
ATP4B P51164 1/20 0.31
HDAC3 O15379 2/20 0.31
HDAC4 P56524 2/20 0.31
HDAC7 Q8WUI4 2/20 0.31
HDAC2 Q92769 2/20 0.31
HDAC10 Q969S8 2/20 0.31
HDAC11 Q96DB2 2/20 0.31
HDAC8 Q9BY41 2/20 0.31
HDAC6 Q9UBN7 2/20 0.31
HDAC9 Q9UKV0 2/20 0.31
HDAC5 Q9UQL6 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25754771 0.93 HDAC1 (0.37) SLC6A2SLC6A4SLC6A3HDAC1GAA
SCHEMBL25755007 0.87 SLC6A2 (0.32) SLC6A2SLC6A4SLC6A3HDAC1HTR4
SCHEMBL25754770 0.87 FAAH (0.42) HDAC1FAAHHDAC3HDAC4HDAC7
SCHEMBL25755012 0.84 SLC6A2 (0.33) SLC6A2SLC6A4SLC6A3HTR4HPGDS
SCHEMBL25755005 0.84 SLC6A2 (0.33) SLC6A2SLC6A4SLC6A3HTR4HPGDS
SCHEMBL25755008 0.82 HTR4 (0.31) SLC6A2SLC6A4SLC6A3HDAC1HTR4
SCHEMBL25755006 0.81 SLC6A2 (0.33) SLC6A2SLC6A4SLC6A3HTR4
SCHEMBL22704634 0.80 SLC6A2 (0.36) SLC6A2SLC6A4SLC6A3HTR4HPGDS
SCHEMBL25754795 0.79 SLC6A2 (0.35) SLC6A2SLC6A4SLC6A3HTR4HPGDS
SCHEMBL25755014 0.79 KDM4E (0.32) SLC6A2SLC6A4SLC6A3HTR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) 2023-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM UCHL3, UBE2L3, ADAM33 SLC6A2 4723/4885SLC6A4 4774/4885SLC6A3 3799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.